Cite
MLA Citation
Maxim Kebenko et al.. “A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.” Oncoimmunology, vol. 7, 2018, p. . http://access.bl.uk/ark:/81055/vdc_100068019091.0x00000e